2. Search Result
Search Result
Results for "

Metap2+Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128147
    MetAP-2-IN-6

    		MetAP Metabolic Disease Cancer
    MetAP-2-IN-6 (4-(4-bromophenyl)-1H-1,2,3-triazole) is a MetAP2 inhibitor. MetAP-2-IN-6 can be used for research in conditions mediated by angiogenesis .
    MetAP-2-IN-6
  • HY-133016
    M8891

    		MetAP Cardiovascular Disease Cancer
    M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 54 nM and a Ki of 4.33 nM. M8891 does not inhibit MetAP-1 (IC50>10 µM) . M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral activity [2].
    M8891
  • HY-119062
    A-800141

    		MetAP CDK Cancer
    A-800141 is an orally active, selective, sulfonamide-based MetAP2 inhibitor (IC50=12 nM) that binds reversibly to MetAP2 and interacts with its manganese ions. A-800141 induces the production of N-terminal methionine-unprocessed GAPDH variants, which in turn triggers G1-phase cell cycle arrest, elevates p21 levels, and reduces the levels of phosphorylated Rb and total cyclin A. A-800141 exhibits anti-angiogenic and tumor growth inhibitory effects, and produces synergistic effects when combined with cytotoxic inhibitors or BCL-2 inhibitors. A-800141 has been widely used in scientific research related to B-cell lymphoma, neuroblastoma, prostate cancer, colon cancer, melanoma and other fields [2] .
    A-800141
  • HY-109188
    Relzomostat

    		MetAP Metabolic Disease
    Relzomostat is a methionine aminopeptidase 2 (MetAP2) inhibitor.Relzomostat may be useful for the research of obesity, type 2 diabetes, and other obesity-associated conditions .
    Relzomostat
  • HY-133016A
    (R)-M8891

    		MetAP Others
    (R)-M8891 (compound R-9) is a less active isomer of M8891. M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor .
    (R)-M8891
  • HY-116861
    A-357300

    		MetAP Cancer
    A-357300 is a reversible and selective MetAP2 inhibitor with IC50s of 0.12 and 57 μM against MetAP2 and MetAP1. A-357300 induces cytostasis by cell cycle arrest at the G1 phase selectively in endothelial cells and in a subset of tumor cells. A-357300 inhibits angiogenesis both in vitro and in vivo and shows potent antitumor efficacy in carcinoma, sarcoma, and neuroblastoma murine models. A-357300 can be used for the studies of neuroblastoma, fibrosarcoma and breast cancer .
    A-357300
  • HY-182482
    SB-587094

    		MetAP Cancer
    SB-587094 is a MetAP-2 inhibitor. SB-587094 inhibits cobalt- and manganese-containing hMetAP2. SB-587094 inhibits endothelial cell proliferation. SB-587094 is applicable to cancer-related research [2].
    SB-587094
  • HY-181643
    YOK24

    		MetAP Infection
    YOK24 is an orally active MetAP2 inhibitor and anti-amoebic agent. YOK24 binds covalently to MetAP2 and inhibits its peptidase activity, where MetAP2 is a protein essential for the proliferation of *Entamoeba histolytica*. YOK24 can be used in the research of amoebiasis .
    YOK24
  • HY-122225
    JNJ-4929821

    		MetAP Cancer
    JNJ-4929821 (Compound 88), a triazole derivative, is a selective Methionine aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 15  nM over MetAP-1. JNJ-4929821 can be used for cancers like liver cancer, colorectal adenocarcinoma and pancreatic cancer research .
    JNJ-4929821
  • HY-133806
    Fumarranol

    		MetAP VEGFR Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Fumarranol, a Fumagillin (HY-B0751) analogue, is a selective type 2 methionine aminopeptidase (MetAP2) inhibitor with a human IC50 of 3.2 μM. Fumarranol inhibits proliferation of bovine aortic endothelial cells and inhibits angiogenesis in a mouse matrigel plug model. Fumarranol can be used for the researches of cancer, diabetic retinopathy, age-related macular degeneration .
    Fumarranol
  • HY-182781
    Anticancer agent 313

    		MetAP Cancer
    Anticancer agent 313 is a MetAP2 inhibitor with an IC50 of 4.11 μM. Anticancer agent 313 activates the transcription factor ATF4 via a non-canonical mTORC1-dependent pathway. Anticancer agent 313 inhibits cancer cell proliferation. Anticancer agent 313 is applicable to the research of breast cancer and pancreatic cancer .
    Anticancer agent 313
  • HY-181644
    NS-181

    		MetAP Infection
    NS-181 is a MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis .
    NS-181
  • HY-182419
    A-849519

    		MetAP Cancer
    A-849519 is a reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 19 nM. A-849519 binds to the active site of the Mn 2+ form of human MetAP-2, where the oxygen atom of one acidic functional group interacts with the manganese ion, and another heteroatom binds to the water molecule above the two manganese ions, thereby functionally inhibiting enzyme activity. A-849519 inhibits the methionine processing activity of MetAP-2 as well as the proliferation of fibrosarcoma cells. A-849519 can be used in studies related to fibrosarcoma [2].
    A-849519

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: